文献速递产科母胎医学

体重指数对胎儿分数随孕周增加及无创DNA检测失败的影响

Influence of Body Mass Index on Fetal Fraction Increase With Gestation and Cell-Free DNA Test Failure.
PubMed 文献 · Obstet Gynecol · 2018-01-01

该横断面研究纳入2013年5月至2018年1月澳大利亚两家胎儿医学诊所的14,223例单胎妊娠,比较不同体重指数(BMI)组胎儿分数随孕周的增加及无创DNA检测无结果和失败率。结果显示BMI≥35组胎儿分数随孕周增加极小,无结果和失败风险显著高于正常BMI组,推迟检测不太可能降低该人群的检测失败率。

要点

  • BMI≥35与正常BMI相比,胎儿分数每周增加0.1 vs 0.3单位,差异有统计学意义。
  • BMI≥35组无结果风险显著升高,平台A的OR为22.0,平台B的OR为8.0。
  • BMI≥35组检测失败风险显著升高,平台A的OR为25.0,平台B的OR为5.8。

核心结论

  • BMI≥35的孕妇胎儿分数随孕周增加极小,推迟检测不太可能降低该人群的检测失败率。

研究设计与样本

  • 横断面研究,纳入2013年5月至2018年1月澳大利亚两家胎儿医学诊所的14,223例单胎妊娠,孕10周起进行无创DNA产前筛查。
  • 使用两种平台之一:平台A筛查8,583例(60.3%),平台B筛查5,640例(39.7%)。

主要发现

  • 在两个平台上,BMI升高组的胎儿分数中位数均较低,无结果率和失败率均较高(P<.001)。
  • 与正常BMI孕妇相比,BMI≥35组胎儿分数每周增加量显著更小:0.1 vs 0.3单位/周,P<.001(两个平台均如此)。
  • 平台A中,BMI≥35组与正常BMI组相比,无结果风险的OR为22.0(95%CI 13.8-35.3;发生率16.6% vs 0.9%),检测失败风险的OR为25.0(95%CI 11.2-55.7;发生率6.4% vs 0.3%)。
  • 平台B中,BMI≥35组与正常BMI组相比,无结果风险的OR为8.0(95%CI 4.1-15.6;发生率7.8% vs 1.0%),检测失败风险的OR为5.8(95%CI 2.0-17.3;发生率2.7% vs 0.5%)。

临床怎么用

  • 作者认为,对于BMI≥35的孕妇,推迟无创DNA检测不太可能降低检测失败率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the influence of body mass index (BMI) on fetal fraction increase with gestational age and on the rates of test failure. METHODS: We performed a cross-sectional study of consecutive singleton pregnancies in which cell-free DNA screening for fetal aneuploidies was performed from 10 weeks of gestation, between May 2013 and January 2018, at two fetal medicine clinics in Australia using one of two different platforms. Maternal characteristics, fetal fraction, and failure after a first attempt ("no-call") and after resampling ("test failure") were recorded. Body mass index was classified as normal (BMI less than 25.0), overweight (BMI 25.0-29.9), obesity class I (BMI 30.0-34.9), and obesity classes II and III (BMI 35.0 or greater). Fetal fraction and proportions of no-call results and test failure were compared between the groups. RESULTS: Of 14,223 singleton pregnancies included, 8,583 (60.3%) were screened with platform A and 5,640 (39.7%) with platform B. Median fetal fraction values were lower, and no-call and failure rates were higher in increased BMI groups across both platforms (P<.001 in both). When compared with women with normal BMIs, women with BMIs of 35 or greater had a significantly smaller increase in fetal fraction (0.1 vs 0.3 units/wk, P<.001, in both platforms). In this subgroup, when compared with women with normal BMIs, the odds ratios for a no-call result were 22.0 (95% CI 13.8-35.3, 16.6% vs 0.9%) and 8.0 (95% CI 4.1-15.6, 7.8% vs 1.0%) and for a failed test were 25.0 (95% CI 11.2-55.7, 6.4% vs 0.3%) and 5.8 (95% CI 2.0-17.3, 2.7% vs 0.5%) using platforms A and B, respectively. CONCLUSION: The increase in fetal fraction throughout gestation in women with BMIs of 35 or above is minimal. Postponing the test is unlikely to reduce test failure rates in this population.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rolnik DL, Yong Y, Lee TJ, et al. Influence of Body Mass Index on Fetal Fraction Increase With Gestation and Cell-Free DNA Test Failure. Obstet Gynecol. 2018. PMID: 29995742. doi:10.1097/AOG.0000000000002752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。